ACUTE DYSTONIA
DEFINITION
Dystonia is a brief or sustained muscle spasm, often with slow
abnormal movements. Although any muscle group may be involved, it
most commonly affects facial muscles (eyes, jaw, tongue).
TOXIC CAUSES
Numerous pharmaceutical agents are associated with acute dystonic
reactions. Important examples include:
Benzamides: metoclopramide
sulpiride
Butyrophenones: haloperidol
Chloroquine and hydroxychloroquine
Cocaine
Levodopa
Lithium
Phenothiazines, especially piperazine compounds:
trifluoperazine
perphenazine
fluphenazine
prochlorperazine
thiethylperazine
Serotonin syndrome and neuroleptic malignant syndrome are specific
toxic syndromes, associated with increased muscle tone, that
require specific management.
NON-TOXIC CAUSES
Degenerative: Spinocerebellar degeneration
Focal dystonias: Blepharospasm
Writer's cramp
Infective: Encephalitis
Tetanus
Metabolic: Thyrotoxicosis
Wilson's disease
Structural: Arterio-venous malformation
Cerebrovascular accident
Tumour
CLINICAL FEATURES
Onset of dystonia may occur up to 20 hours following the
administration of the causative agent.
Various types of dystonia, involving particular muscle groups have
been described:
Laryngeal dystonia - spasm of pharyngeal and laryngeal muscles
resulting in stridor.
Oculogyric crisis - spasm of extra-ocular muscles, forcing the
eyes into upward or lateral gaze.
Opisthotonus - spasm of all paravertebral muscles, forcing the
trunk and neck into hyperextension.
Retrocollis - spasm of paravertebral neck muscles, forcing the
neck into hyperextension.
Torticollis - spasm of lateral neck muscles, twisting the neck
to one side.
DIFFERENTIAL DIAGNOSIS
Catatonic states
Dyskinesias
Seizures (tonic phase)
RELEVANT INVESTIGATIONS
Usually, no specific investigations are required to evaluate acute
toxic dystonias. Where indicated, the following may be useful:
CPK
EEG or CT scan of head (to exclude seizures or central organic
lesions)
Toxicology screens
Urinalysis
TREATMENT
Dystonias may increase in severity after initial presentation and
therefore all patients should be treated. Initial treatment is
usually provided with a parenteral formulation, followed by oral
medication for 2 to 3 days to prevent recurrence. Milder forms can
be treated with oral medication alone.
Suggested agents include:
Benztropine 1 to 2 mg by intramuscular or intravenous injection
(0.02 mg/kg in children). This dose may be repeated in 10 minutes
if the response is incomplete and anticholinergic side effects have
not occurred. Follow with 1 mg (0.02 mg/kg in children) orally
every 12 hours for 2 days. Benztropine is not the agent of choice
in children less than 3 years of age.
Diphenhydramine 1 mg/kg intravenously or intramuscularly to a
maximum of 30 mg. This dose may be repeated in 30 minutes if the
response is incomplete and anticholinergic side effects have not
occurred. Follow with 25 mg (0.5 mg/kg in children) orally, every
6 hours for 2 days.
Diazepam 0.1 mg/kg by slow intravenous injection. This dose may
by repeated in 30 minutes if the response is incomplete and
excessive sedation has not occurred.
Procyclidine 5 to 10 mg (0.5 to 2 mg in children under 2 years
of age, 2 to 5 mg in children over 2 years of age) intramuscularly
or intravenously. This dose may be repeated after 20 minutes if
the response is incomplete. Follow with 2.5 mg orally every 8
hours for 2 days.
CLINICAL COURSE AND MONITORING
Patients should be observed until symptom free. Prior to
discharge, they should be instructed that recurrent dystonia can
occur for up to 48 hours. In this event, they should return for
medical evaluation. The clinical course may be prolonged in the
case of dystonic reactions following injection of depot
preparations.
LONG-TERM COMPLICATIONS
Unusual.
AUTHOR(S)/PEER REVIEW
Author: Robert Dowsett
Consultant Toxicologist
Departments of Clinical Pharmacology and Emergency
Medicine
Westmead Hospital
Westmead, NSW 2145
Australia
Peer Review: London, March 1998: P. Dargan, T. Della Puppa, L.
Murray, A. Nantel, M. Nicholls.